Progyny (PGNY) Expected to Announce Earnings on Thursday

Progyny (NASDAQ:PGNY) is projected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $326.4650 million for the quarter. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:45 PM ET.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. During the same period in the previous year, the company earned $0.42 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Price Performance

Shares of Progyny stock traded down $0.15 during trading on Wednesday, reaching $18.83. 240,895 shares of the company traded hands, compared to its average volume of 1,481,072. Progyny has a 1-year low of $16.10 and a 1-year high of $28.75. The firm has a market capitalization of $1.47 billion, a PE ratio of 29.02, a P/E/G ratio of 1.09 and a beta of 0.91. The company has a 50 day moving average price of $17.96 and a 200-day moving average price of $21.71.

Insider Activity

In other news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the sale, the executive vice president owned 89,879 shares in the company, valued at $1,563,894.60. This represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 7,455 shares of company stock valued at $129,515 in the last ninety days. 9.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Progyny

Institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd bought a new position in Progyny in the 4th quarter worth approximately $25,000. Canada Pension Plan Investment Board acquired a new position in Progyny in the 2nd quarter worth $77,000. Quarry LP boosted its stake in Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after purchasing an additional 3,427 shares during the period. Tower Research Capital LLC TRC boosted its stake in Progyny by 203.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock worth $154,000 after purchasing an additional 4,708 shares during the period. Finally, Entropy Technologies LP acquired a new position in Progyny in the 4th quarter worth $203,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PGNY. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Truist Financial cut their price target on Progyny from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. KeyCorp dropped their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Progyny currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.91.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.